Restricted accessResearch articleFirst published online 2013-07
Carbenoxolone Enhances TRAIL -Induced Apoptosis Through the Upregulation of Death Receptor 5 and Inhibition of Gap Junction Intercellular Communication in Human Glioma
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been used extensively in cancer therapy. However, more than half of glioblastoma multiforme are insensitive to the apoptotic effect of TRAIL. Improvement in therapeutic modalities that enhances the efficacy of TRAIL in glioma is much sought after. In this study, we combined the tumor selectivity of TRAIL and tumor-homing properties of mesenchymal stem cells (MSC) with gap junction (GJ) inhibitory effect of carbenoxolone (CBX) to target orthotopic glioma. MSC were engineered to express TRAIL (MSC-TRAIL) by incorporating the secretable trimeric form of TRAIL into a Herpes Simplex Virus (HSV) type I amplicon vector. Our results showed that combined treatment of MSC-TRAIL and CBX enhanced glioma cell death, especially in three primary human glioma isolates, of which two of those are marginally sensitive to TRAIL. CBX enhanced TRAIL-induced apoptosis through upregulation of death receptor 5, blockade of GJ intercellular communication, and downregulation of connexin 43. Dual arm therapy using TRAIL and CBX prolonged the survival of treated mice by ∼27% when compared with the controls in an intracranial glioma model. The enhanced efficacy of TRAIL in combination with CBX coupled with the minimal cytotoxic nature of CBX suggested a favorable clinical usage of this treatment regimen.
Get full access to this article
View all access options for this article.
References
1.
LowensteinPR. 2010. Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J Clin Oncol, 28:4670–4673.
2.
GriffithTS, StokesB, KucabaTA, EarelJKJr., VanOostenRL, BrincksEL, NorianLA. 2009. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther, 9:9–19.
3.
BellailAC, QiL, MulliganP, ChhabraV, HaoC. 2009. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials, 4:34–41.
4.
ThorburnA, BehbakhtK, FordH. 2008. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat, 11:17–24.
GantenTM, KoschnyR, SykoraJ, Schulze-BergkamenH, BuchlerP, HaasTL, SchaderMB, UntergasserA, StremmelW, WalczakH. 2006. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res, 12:2640–2646.
7.
ZhangY, ZhangB. 2008. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res, 6:1861–1871.
8.
ZhangL, ZhuH, TeraishiF, DavisJJ, GuoW, FanZ, FangB. 2005. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia, 7:594–602.
9.
HaagC, StadelD, ZhouS, BachemMG, MollerP, DebatinKM, FuldaS. 2010. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut, 60:225–237.
10.
HingtgenS, RenX, TerwilligerE, ClassonM, WeisslederR, ShahK. 2008. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther, 7:3575–3585.
11.
SoriaJC, SmitE, KhayatD, BesseB, YangX, HsuCP, ReeseD, WiezorekJ, BlackhallF. 2010. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol, 28:1527–1533.
12.
Bagci-OnderT, WakimotoH, AndereggM, CameronC, ShahK. 2010. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res, 71:154–163.
13.
NaumannI, KapplerR, von SchweinitzD, DebatinKM, FuldaS. 2011. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res, 17:3204–3218.
14.
BangertA, CristofanonS, EckhardtI, AbhariBA, KolodziejS, HackerS, VellankiSH, LausenJ, DebatinKM, FuldaS. 2012. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene, 31:4677–4688.
15.
WesthoffMA, ZhouS, BachemMG, DebatinKM, FuldaS. 2008. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene, 27:5169–5181.
16.
WilleckeK, EibergerJ, DegenJ, EckardtD, RomualdiA, GuldenagelM, DeutschU, SohlG. 2002. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem, 383:725–737.
17.
SagarGD, LarsonDM. 2006. Carbenoxolone inhibits junctional transfer and upregulates Connexin43 expression by a protein kinase A-dependent pathway. J Cell Biochem, 98:1543–1551.
18.
OliveiraR, ChristovC, GuillamoJS, de BouardS, PalfiS, VenanceL, TardyM, PeschanskiM. 2005. Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol, 6:7.
19.
Drug information online. Drugs.com2011. Carbenoxolone. www.drugs.com/international/carbenoxolone.html. 2013 March 18.
20.
DavidsonJS, BaumgartenIM. 1988. Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships. J Pharmacol Exp Ther, 246:1104–1107.
DeakE, SeifriedE, HenschlerR. 2010. Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol, 29:514–529.
23.
HoIA, ChanKY, NgWH, GuoCM, HuiKM, CheangP, LamPY. 2009. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells, 27:1366–1375.
24.
MuellerLP, LuetzkendorfJ, WidderM, NergerK, CaysaH, MuellerT. 2011. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther, 18:229–239.
25.
HoIA, ChanKY, MiaoL, ShimWS, GuoCM, CheangP, HuiKM, LamPY. 2008. HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells. Cancer Gene Ther, 15:553–562.
26.
CarlsonBL, PokornyJL, SchroederMA, SarkariaJN. 2011. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol, 14,14:16.
27.
DavidsonJS, BaumgartenIM, HarleyEH. 1986. Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochem Biophys Res Commun, 134:29–36.
28.
WangS. 2008. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene, 27:6207–6215.
29.
Herrero-GonzalezS, Valle-CasusoJC, Sanchez-AlvarezR, GiaumeC, MedinaJM, TaberneroA. 2009. Connexin43 is involved in the effect of endothelin-1 on astrocyte proliferation and glucose uptake. Glia, 57:222–233.
30.
LampePD, LauAF. 2004. The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol, 36:1171–1186.
31.
HerbstRS, EckhardtSG, KurzrockR, EbbinghausS, O'DwyerPJ, GordonMS, NovotnyW, GoldwasserMA, TohnyaTMet al.2010. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol, 28:2839–2846.
32.
PlotkinLI, ManolagasSC, BellidoT. 2002. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem, 277:8648–8657.
33.
MesnilM, CrespinS, AvanzoJL, Zaidan-DagliML. 2005. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta, 1719:125–145.
34.
CottinS, GouldPV, CantinL, CarusoM. 2011. Gap junctions in human glioblastomas: implications for suicide gene therapy. Cancer Gene Ther, 18:674–681.
35.
CottinS, GhaniK, CarusoM. 2008. Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. Cancer Gene Ther, 15:823–831.
36.
BoenglerK, DodoniG, Rodriguez-SinovasA, CabestreroA, Ruiz-MeanaM, GresP, KonietzkaI, Lopez-IglesiasC, Garcia-DoradoDet al.2005. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res, 67:234–244.
37.
Rodriguez-SinovasA, BoenglerK, CabestreroA, GresP, MorenteM, Ruiz-MeanaM, KonietzkaI, MiroE, TotzeckAet al.2006. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ Res, 99:93–101.
38.
Ruiz-MeanaM, Rodriguez-SinovasA, CabestreroA, BoenglerK, HeuschG, Garcia-DoradoD. 2008. Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia-reperfusion injury. Cardiovasc Res, 77:325–333.
39.
JensenK, PatelA, Klubo-GwiezdzinskaJ, BauerA, VaskoV. 2011. Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis. Endocr Relat Cancer, 18:613–626.
40.
SharrowAC, LiY, MicsenyiA, GriswoldRD, WellsA, MongaSS, BlairHC. 2008. Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL. Exp Cell Res, 314:297–308.
41.
HaoJL, SuzukiK, LuY, HiranoS, FukudaK, KumagaiN, KimuraK, NishidaT. 2005. Inhibition of gap junction-mediated intercellular communication by TNF-alpha in cultured human corneal fibroblasts. Invest Ophthalmol Vis Sci, 46:1195–1200.
42.
TheissC, MazurA, MellerK, MannherzHG. 2007. Changes in gap junction organization and decreased coupling during induced apoptosis in lens epithelial and NIH-3T3 cells. Exp Cell Res, 313:38–52.
43.
ZundorfG, KahlertS, ReiserG. 2007. Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture. J Neurochem, 102:508–521.
44.
ShenoyK, WuY, PervaizS. 2009. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res, 69:1941–1950.
45.
YodkeereeS, SungB, LimtrakulP, AggarwalBB. 2009. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res, 69:6581–6589.
46.
PrasadS, RavindranJ, SungB, PandeyMK, AggarwalBB. 2010. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther, 9:856–868.
47.
OlbinaG, EckhartW. 2003. Mutations in the second extracellular region of connexin 43 prevent localization to the plasma membrane, but do not affect its ability to suppress cell growth. Mol Cancer Res, 1:690–700.
48.
Herrero-GonzalezS, GangosoE, GiaumeC, NausCC, MedinaJM, TaberneroA. 2010. Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells. Oncogene, 29:5712–5723.
49.
GiardinaSF, MikamiM, GoubaevaF, YangJ. 2007. Connexin 43 confers resistance to hydrogen peroxide-mediated apoptosis. Biochem Biophys Res Commun, 362:747–752.
50.
LeeHJ, LeeHJ, SohnEJ, LeeEO, KimJH, LeeMH, KimSH. 2012. Inhibition of connexin 26/43 and extracellular-regulated kinase protein plays a critical role in melatonin facilitated gap junctional intercellular communication in hydrogen peroxide-treated HaCaT keratinocyte cells. Evid Based Complement Alternat Med, 2012:589365.
51.
ParkEJ, ChoiKS, YooYH, KwonTK. 2012. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs, 24:260–269.
52.
YouRI, ChangYC, ChenPM, WangWS, HsuTL, YangCY, LeeCT, HsiehSL. 2008. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3)Blood, 111:1480–1488.
53.
SiaKC, ChongWK, HoIA, YulyanaY, EndayaB, HuynhH, LamPY. 2010. Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. J Gene Med, 12:848–858.
54.
LeshchenkoY, LikhodiiS, YueW, BurnhamWM, Perez VelazquezJL. 2006. Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci, 7:3.
55.
KelleySK, HarrisLA, XieD, DeforgeL, TotpalK, BussiereJ, FoxJA. 2001. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther, 299:31–38.
56.
RozanovDV, SavinovAY, GolubkovVS, RozanovaOL, PostnovaTI, SergienkoEA, VasileS, AleshinAE, RegaMF, PellecchiaM, StronginAY. 2009. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther, 8:1515–1525.
57.
StuppR, HegiME, MasonWP, van den BentMJ, TaphoornMJ, JanzerRC, LudwinSK, AllgeierA, FisherBet al.2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10:459–466.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
